Best And Worst Performing Biotech Stocks In the Second Quarter

IBB ChartIBB data by YCharts

BOSTON ( TheStreet) -- Biotech investors will be happy with the chart above as the sector's benchmark index continues to outperform the broader market in the second quarter.

The iShares Nasdaq Biotechnology Index Fund closed the June quarter up 8.9 percent compared to a 2.8 percent rise in the S&P 500. The biotech index has been on a consistent downtrend since the middle of May, which bears watching.

Here are the five top-performing bio-pharma stocks in the second quarter:

No. 5: Vanda Pharmaceuticals ( VNDA) VNDA Chart VNDA data by YCharts

Vanda is developing tasimelteon as a treatment for a rare sleep disorder which affects blind people. Vanda shares fell in June after questions were raised about the company's clinical development of tasimelteon, raising the risk that the drug would be rejected by FDA.

No. 4: Stemline Therapeutics ( STML) STML Chart STML data by YCharts

Stemline is developing drugs which target cancer stem cells. The company's shares rose following the presentation of clinical data at the American Society of Clinical Oncology annual meeting in early June.

No. 3: Immunomedics ( IMMU) IMMU Chart IMMU data by YCharts

Immunomedics will be presenting results from a phase I study of the experimental radio-labeled monoclonal antibody Clivatuzumab tetraxetan at a medical meeting, July 3-6.

No. 2: Acadia Pharmaceuticals ( ACAD) ACAD Chart ACAD data by YCharts

Acadia continues to be one of the strongest-performing stocks in the biotech sector this year, supported by investor excitement for the company's Parkinson's psychosis drug pimavanserin.

No. 1: Clovis Oncology ( ACAD) CLVS Chart CLVS data by YCharts

Clovis is not only the best-performing stock in the second quarter, but it's also No. 1 for all of 2013 so far. Why? The experimental lung cancer drug CO-1686.

Not all bio-pharma stocks enjoyed success in the second quarter. The worst-performing stocks for the June quarter were:

No. 5: Cardium Therapeutics ( CXM) -56%
No. 4: Aveo Pharmaceuticals ( AVEO) -66%
No. 3: Infinity Pharmaceuticals ( INFI) -67%
No. 2: Echo Therapeutics ( ECTE) -68%

No. 1: GenVec ( GNVC): -75%

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

More from Stocks

Tech Stocks Have You Baffled? Educate Yourself in Some Portfolio Diversification

Tech Stocks Have You Baffled? Educate Yourself in Some Portfolio Diversification

Alphabet Shares Rise on Earnings, Revenue Beat But Some Concerns Remain

Alphabet Shares Rise on Earnings, Revenue Beat But Some Concerns Remain

Semiconductor Stocks Get Smashed Again as Earnings Weakness Continues
Dow and Nasdaq Finish Lower as 10-Year Treasury Yield Hovers Near 3%

Dow and Nasdaq Finish Lower as 10-Year Treasury Yield Hovers Near 3%

Video: Jim Cramer on Trade Tariffs, Rising Rates, Kimberly Clark and Hasbro

Video: Jim Cramer on Trade Tariffs, Rising Rates, Kimberly Clark and Hasbro